Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer

被引:12
|
作者
Yang, Wensha [1 ]
Reznik, Robert [1 ]
Fraass, Benedick A. [1 ]
Nissen, Nicholas [2 ]
Hendifar, Andrew [3 ]
Wachsman, Ashley [4 ]
Sandler, Howard [1 ]
Tuli, Richard [1 ]
机构
[1] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, Dept Gastrointestinal Oncol, Los Angeles, CA 90048 USA
[4] Cedars Sinai Med Ctr, Dept Cross Sect Imaging Intervent Oncol, Los Angeles, CA 90048 USA
关键词
SBRT; Pancreas; SIB; Simultaneously integrated boost; RADIOTHERAPY; GEMCITABINE; ADENOCARCINOMA; HEAD;
D O I
10.1016/j.meddos.2014.09.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Stereotactic body radiation therapy (SBRT) provides a promising way to treat locally advanced pancreatic cancer and borderline resectable pancreatic cancer. A simultaneous integrated boost (SIB) to the region of vessel abutment or encasement during SBRT has the potential to downstage otherwise likely positive surgical margins. Despite the potential benefit of using SIB-SBRT, the ability to boost is limited by the local geometry of the organs at risk (OARs), such as stomach, duodenum, and bowel (SDB), relative to tumor. In this study, we have retrospectively replanned 20 patients with 25 Gy prescribed to the planning target volume (PTV) and 33 similar to 80 Gy to the boost target volume (BTV) using an SIB technique for all patients. The number of plans and patients able to satisfy a set of clinically established constraints is analyzed. The ability to boost vessels (within the gross target volume [GTV]) is shown to correlate with the overlap volume (OLV), defined to be the overlap between the GTV + a 1(OLV1)- or 2(OLV2)-cm margin with the union of SDB. Integral dose, boost dose contrast (BDC), biologically effective BDC, tumor control probability for BTV, and normal tissue complication probabilities are used to analyze the dosimetric results. More than 65% of the cases can deliver a boost to 40 Gy while satisfying all OAR constraints. An OLV2 of 100 cm(3) is identified as the cutoff volume: for cases with OLV2 larger than 100 cm(3), it is very unlikely the case could achieve 25 Gy to the PTV while successfully meeting all the OAR constraints. (C) 2015 American Association of Medical Dosimetrists.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 50 条
  • [1] Elective Nodal Irradiation With Simultaneous Integrated Boost Stereotactic Body Radiation Therapy for Pancreatic Cancer
    Nakamura, A.
    Prichard, H. A.
    Wo, J. Y.
    Wolfgang, J. A.
    Hong, T. I.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E210 - E210
  • [2] Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma
    Simoni, N.
    Micera, R.
    Paiella, S.
    Guariglia, S.
    Zivelonghi, E.
    Malleo, G.
    Rossi, G.
    Addari, L.
    Giuliani, T.
    Pollini, T.
    Cavedon, C.
    Salvia, R.
    Milella, M.
    Bassi, C.
    Mazzarotto, R.
    [J]. CLINICAL ONCOLOGY, 2021, 33 (01) : E31 - E38
  • [3] MR Guided Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost to Dominant Intraprostatic Lesions for Prostate Cancer: A Retrospective Dosimetric Study
    Du, D.
    Lee, J.
    Pantelic, M.
    Hurst, N.
    Movsas, B.
    Chetty, I.
    Wen, N.
    [J]. MEDICAL PHYSICS, 2019, 46 (06) : E268 - E268
  • [4] Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost in Patients With Spinal Metastases
    Pontoriero, Antonio
    Iati, Giuseppe
    Cacciola, Alberto
    Conti, Alfredo
    Brogna, Anna
    Siragusa, Carmelo
    Ferini, Gianluca
    Davi, Valerio
    Tamburella, Consuelo
    Molino, Laura
    Cambareri, Domenico
    Severo, Cesare
    Parisi, Silvana
    Settineri, Nicola
    Ielo, Isidora
    Pergolizzi, Stefano
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [5] STEREOTACTIC BODY RADIATION THERAPY BOOST IN LOCALLY ADVANCED PANCREATIC CANCER
    Seo, YoungSeok
    Kim, Mi-Sook
    Yoo, SungYul
    Cho, ChulKoo
    Yang, KwangMo
    Yoo, HyungJun
    Choi, ChulWon
    Lee, DongHan
    Kim, Jin
    Kim, Min Suk
    Kang, HyeJin
    Kim, YoungHan
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05): : 1456 - 1461
  • [6] Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy
    Liu, Peilin
    Gao, Xian-shu
    Wang, Zishen
    Li, Xiaomei
    Xi, Cao
    Jia, Chenghao
    Xie, Mu
    Lyu, Feng
    Ding, Xuanfeng
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Dosimetric Analysis of Organs at Risk During Expiratory Gating in Stereotactic Body Radiation Therapy for Pancreatic Cancer
    Taniguchi, Cullen M.
    Murphy, James D.
    Eclov, Neville
    Atwood, Todd F.
    Phd, Kayla N. Kielar
    Christman-Skieller, Claudia
    Mok, Ed
    Xing, Lei
    Koong, Albert C.
    Chang, Daniel T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (04): : 1090 - 1095
  • [8] Dosimetric Comparison of RapidArc versus CyberKnife for Stereotactic Body Radiation Therapy for Pancreatic Cancer
    Atwood, T. F.
    Mok, E.
    Lo, A.
    Xing, L.
    Koong, A. C.
    Chang, D. T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S345 - S346
  • [9] Dosimetric Analysis of Kidney Toxicity After Stereotactic Body Radiation Therapy for Pancreatic Cancer
    Bhirud, A. R.
    Lin, C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S313 - S313
  • [10] Stereotactic Body Radiation Therapy for Pancreatic Cancer
    Goodman, Karyn A.
    [J]. CANCER JOURNAL, 2016, 22 (04): : 290 - 295